Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Corvus Pharmaceuticals (CRVS) Leases (2019 - 2026)

Corvus Pharmaceuticals' Leases history spans 8 years, with the latest figure at $751000.0 for Q1 2026.

  • Quarterly Leases fell 31.42% to $751000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $751000.0 through Mar 2026, down 31.42% year-over-year, with the annual reading at $839000.0 for FY2025, 28.72% down from the prior year.
  • Leases came in at $751000.0 for Q1 2026, down from $839000.0 in the prior quarter.
  • In the past five years, Leases ranged from a high of $3.0 million in Q1 2022 to a low of $300000.0 in Q3 2024.
  • The 5-year median for Leases is $1.1 million (2023), against an average of $1.4 million.
  • Year-over-year, Leases plummeted 78.57% in 2024 and then soared 209.0% in 2025.
  • Corvus Pharmaceuticals' Leases stood at $2.2 million in 2022, then tumbled by 47.77% to $1.1 million in 2023, then rose by 2.44% to $1.2 million in 2024, then dropped by 28.72% to $839000.0 in 2025, then fell by 10.49% to $751000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Leases are $751000.0 (Q1 2026), $839000.0 (Q4 2025), and $927000.0 (Q3 2025).